Physician profile
Ali Sorrell
NPI 1003479601
$3,042.83
in general payments reported to CMS, 2019-2025
32 companies · $1,557 in 2025
The $1,557 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,486 · 2025: $1,557.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,043.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,042.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $539.63 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $485.23 | 2024-2025 | Breztri, Airsupra, Farxiga |
| Abbvie INC. | $348.81 | 2024-2025 | |
| Lilly USA, LLC | $247.09 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Cequr Corporation | $159.57 | 2024-2025 | Cequr Simplicity |
| Corcept Therapeutics | $122.30 | 2024-2025 | Korlym |
| Sequel Med Tech, LLC | $121.80 | 2025 | Twiist |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $84.17 | 2024-2025 | Caplyta |
| Medtronic, INC. | $81.59 | 2024-2025 | Minimed 780g |
| Antares Pharma, INC. | $77.38 | 2024-2025 | Xyosted |
| Exact Sciences Corporation | $72.54 | 2024-2025 | Cologuard Collection Kit |
| Xeris Pharmaceuticals, INC. | $70.31 | 2024-2025 | Gvoke Hypopen, Recorlev |
| Axsome Therapeutics, INC. | $63.83 | 2025 | Auvelity |
| Sumitomo Pharma America, INC. | $59.38 | 2024-2025 | Gemtesa |
| Insulet Corporation | $59.24 | 2024-2025 | Omnipod |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $51.87 | 2024-2025 | Veozah, Myrbetriq |
| Otsuka America Pharmaceutical, INC. | $51.25 | 2024 | Rexulti |
| Novartis Pharmaceuticals Corporation | $50.14 | 2024-2025 | |
| Mannkind Corporation | $40.91 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.60 | 2024 | Jardiance |
| Amgen INC. | $29.02 | 2024 | Otezla, Repatha |
| Dexcom, INC. | $25.39 | 2024 | Dexcom G6 Transmitter |
| Alexion Pharmaceuticals, INC. | $21.35 | 2024 | Strensiq |
| Shield Therapeutics INC | $20.81 | 2024 | |
| Radius Health, INC. | $19.79 | 2024 | Tymlos |
| Amneal Pharmaceuticals LLC | $16.96 | 2024 | Unithroid |
| Azurity Pharmaceuticals, INC. | $16.58 | 2025 | Azmiro |
| Ascendis Pharma Endocrinology INC | $15.97 | 2025 | Yorvipath |
| Takeda Pharmaceuticals U.S.A., INC. | $15.76 | 2025 | Trintellix |
| Ibsa Pharma INC. | $15.66 | 2024 | Tirosint, Licart |
| Glaxosmithkline, LLC. | $14.74 | 2024 | Trelegy Ellipta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.16 | 2024 | Xifaxan, Trulance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ali Sorrell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.